Stoke Therapeutics announced the appointment of Jason Hoitt as Chief Commercial Officer. Mr. Hoitt has more than 20 years of experience successfully planning and executing commercial strategies at leading biopharma companies. As Chief Commercial Officer and a member of Stoke’s leadership team, Mr. Hoitt will be responsible for overseeing the Company’s global commercial strategy for STK-001. Recently announced data support the potential for STK-001 to be the first disease-modifying medicine for the treatment of Dravet syndrome.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on STOK:
- Stoke Stock (NASDAQ:STOK) Gains on Drug Update; Is There More Upside Left?
- Stoke Therapeutics Launches Public Offering for Clinical Development
- Biotech Alert: Searches spiking for these stocks today
- Stoke Therapeutics 5.556M share Secondary priced at $13.50
- Stoke Therapeutics announces $75M common stock offering
